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typhlitis in children and to determine risk factors for its develop-
ment.
Methods: We reviewed the medical records of pediatric cancer pa-
tients with typhlitis from 1995 to 2005 for clinical, laboratory and
radiographic findings, and compared them to a control group of
cancer patients hospitalized during the same period without ty-
phlitis.
Results: During the study period 843 patients were diagnosed with
cancer at the Schneider Children' s Medical Center. Among them,
there were 52 episodes of typhlitis in 42 patients (5%), of whom, 32
were treated for hematological malignancies (76%). The incidence
was highest in patients with AML and Burkitt' s lymphoma (15%
and 12%, respectively). The most common clinical findings were
abdominal pain (89%) abdominal tenderness (83%), fever (75%) and
mucositis (58%). Only 50% had severe neutropenia (<100 ANC) on
admission. All patients had abdominal X-RAY while abdominal US
and CT were performed in 23% and 11% of patients, respectively.
The latter imaging methods did not contribute to the diagnosis
or the management of our patients. All patients were treated
conservatively with a 100% survival rate. In multivariate analysis,
mucositis (OR-30.7), history of bone marrow transplantation
OR-58.9) and use of chemotherapy in the two weeks preceding the
typhlitis (OR-12.9) were significantly associated with typhlitis.
Conclusions: The incidence of typhlitis is increasing compared
to previous studies. The highest incidence was among AML and
Burkitt' s lymphoma patients. Although severe neutropenia was
identified as a significant risk factor, it was absent in 50% of the
cases. Mucositis, history of BMT and chemotherapy in the preceding
two weeks were major independent risk factors. Most of pediatric
patients with Typhlitis may be treated conservatively with excel-
lent results. The high survival rate may be attributed to high index
of suspicion and prompt therapy.
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Background: Neutropenic patients may develop secondary infec-
tions (SI) during the treatment of primary infections (PI).
Objectives: To identify predictive variables of secondary infections
among febrile neutropenic patients (FNP) who respond to initial
antibiotic therapy, and analyze whether SI increase mortality.
Methods: FNP with acute leukemia, other haematologic diseases,
solid tumors and drug induced neutropenia were eligible. Only the
first episode of febrile neutropenia of each patient during the
period 1997-2007 was included, and those who did not respond
to initial antibiotic treatment were excluded. Variables assessed
were: age, sex, underlying disease, hematopoietic stem cell trans-
plantation, in-patient at the time of primary infection (IPI), pres-
ence of central catheter, severity of neutropenia (<100 vs. 100-500
PMN/mm3 presence of focus and/or bacteremia at PI, previous an-
timicrobial prophylaxis and initial empiric antibiotic therapy.
Results: Of the 403 FNP with their first episode of febrile neutrope-
nia, 299 responded to initial antibiotic regimen and therefore were
considered for our analysis. SI were observed in 64/299(21.4%).
Forward and backward stepwise multiple logistic regression test
were performed and we obtained a model with 6 predictive vari-
ables: age under 40 (odds ratio (OR) 2.77 [95% CI 1.36-5.63], p=
0.005); acute myeloblastic leukemia (AML)(OR 13.31 [95% CI 6.14-
28.86], p=0.001); severe neutropenia (OR 2.24 [95% CI 1.02-4.93],
p=0.044); focus at PI (OR 2.60 [95% CI 1.22-5.57], p=0.013); bac-
teremia at PI (OR 3.21 [95% CI 1.46-7.05], p=0.004); and IPI (OR
2.36 [95% CI 1.18-4.68], p=0.014). When none of the predictive
variables were present, the probability of SI was 1.3%, and when
the 6 variables were present, it was 95.6%. A score system to pre-
dict the probability of SI was performed. In the multivariate analy-
sis, predictive variables associated with mortality were bacteremia
in PI (OR 7.8 [95% CI 2.4-24], p<0.001) and SI (OR 4.4 [95% CI 1.4-
13], p=0.01). Mortality was 14% in PNF with SI, and 2.5% without SI
(p<0.001).
Conclusions: The predictive variables of SI were: AML, age under
40, severe neutropenia, IPI, and bacteremia and focus in PI. The
presence of bacteremia in the PI and the development of SI were
interpreted as prognostic factors. Our scoring system must be val-
idated in a prospective study.
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Background: Fever in neutropenic patient requires immediate
broad-spectrum antibiotic treatment. However, such patients do
not represent a homogeneous population and the majority of them
are at low risk of developing infectious complication. Several stud-
ies and recent meta-analysis have shown that intravenous antibi-
otics may be substituted by oral antibiotics safely in low risk pa-
tients with febrile neutropenia (FN). Moxifloxacin, a new broad
spectrum quinolone, is an alternative to treat these patients.
Objective: To evaluate the use of oral moxifloxacin in oncologic
pediatric patients with FN.
Methods: We conducted a prospective study in patients submitted
to chemotherapy and FN, from the ages of 3 to 21 years old, with
solid tumors, remission acute lymphoid leukemia (ALL), and lym-
phomas (L) without co-morbidities and treated as outpatient with
oral Moxifloxacina, (15mg/body weight/day -max. 600mg/day) ad-
ministered orally once a day. Safety and adverse events were mon-
itored at the beginning and after each seven days of treatment,
with evaluation of renal and hepatic functions, glicemia and EKG.
Results: Between October 2005 and November 2007, 144 episodes
of FN were included (90 patients). We evaluated 123 episodes (89
patients), being 50.6% males with a median age of 11.3 years.
25.8% corresponded to patients with ALL, 15.7 OS, 12.4% CNS tu-
mors, 9.0% NB, 7.9% Ewing S., 6.7% RMS, 5.6% L, 2.2% Wilms tu-
mors 1.1% PNET, and 13.5% other tumors. 9.8% of the episodes had
a CVC. Analyzing the 106 complete episodes, the average duration
of neutropenia (ANC < 500 cells) was 4.8 days (range, 1-16 days),
the average duration of fever was 2.2 days (range 1-8 days); the av-
erage duration of the treatment was 8.2 days (range 5-21 days).In
the last clinical evaluation, 67% were FUO, 15.1% were MDI and
17.9% were CDI. No patient died. Successful treatment occurred in
84.5% of episodes, 79.6% without modifications (exclusively with
moxifloxacin as outpatient). The reasons for failure of treatment
(19/15,5%) were clinical status deterioration in 4 patients persis-
tent fever (2) and microbiologic evidence (8) an adverse event in
four (vomiting and plateletpenia). No serious adverse events were
observed.
Conclusion: This non-randomized study shows that oral moxiflox-
acin appears effective, safe, convenient, and well-tolerated agent
for the outpatient management of low-risk episodes of chemother-
apy induced FN in pediatric patients in our particular setting.
